Clinical trial
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML…
NCT00053287 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00053287 |
|---|---|
| Title | Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS |
| Official title | Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases |
| Intervention type | Drug |
| Interventions | carboplatin, fludarabine phosphate, thalidomide, topotecan hydrochloride |
| Enrollment | 42 |
| Start date | Sep 1, 2002 |
| Primary completion | Jan 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jan 28, 2003 |
| Last update posted | Jun 10, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: